Evidence map›Paper›PMID 36495130›Full record

ArticleMolecular oncology2023

Cerebrospinal fluid circulating tumor DNA depicts profiling of brain metastasis in NSCLC.

Jun Wu, Zhiqiang Liu, Tianxiang Huang, Ying Wang, Meng Meng Song, Tao Song, Gretchen Long, Xiaobing Zhang, Xi Li, Longbo Zhang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed, 3 pooled it
3.7field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 3 syntheses or guidelines pooled it, 42 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Value and research advances of ctDNA in perioperative therapy for non-small cell lung cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 4 countries.

Jun WuDepartment of Neurosurgery, Xiangya Hospital, Central South University, Changsha, China.
Zhiqiang LiuDepartment of Neuroscience, Erasmus Medical Center, Erasmus University Rotterdam, The Netherlands.
Tianxiang HuangDepartment of Neurosurgery, Yale School of Medicine, New Haven, CT, USA.
Ying WangDepartment of Neurosurgery, Xiangya Hospital, Central South University, Changsha, China.
Meng Meng SongGeneplus-Beijing Institute, China.ORCID 0000-0003-3820-2540
Tao SongDepartment of Neurosurgery, Xiangya Hospital, Central South University, Changsha, China.
Gretchen LongDepartment of Neurosurgery, Yale School of Medicine, New Haven, CT, USA.
Xiaobing ZhangDepartment of Psychology, Florida State University, Tallahassee, FL, USA.
Xi LiHunan Key Laboratory of Pharmacogenetics, Xiangya Hospital, Central South University, Changsha, China.
Longbo ZhangDepartment of Neurosurgery, Xiangya Hospital, Central South University, Changsha, China.ORCID 0000-0002-9077-3239
Central South University · CNYale University · USErasmus MC · NLFlorida State University · USGenePath Dx (India) · IN

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
NCATS NIH HHS UL1 TR001863
6 · The paper itself

Abstract

Brain metastasis (BM) genetically diverges from the primary tumor in non-small-cell lung cancer (NSCLC). Hence, accurately capturing clinically relevant alterations is pivotal for the delivery of targeted therapies. Circulating tumor DNA (ctDNA) sequencing has emerged as a promising liquid biopsy in the biomarker-based clinical management of recurrent and extracranial metastatic NSCLC. However, the absence of simultaneous sequencing data from brain metastatic sites prevents the definitive evaluation of the efficacy of ctDNA in representing genetic profiles in BM. Here, we performed parallel genomic comparisons between matched BM and primary tumor DNA, plasma ctDNA, and cerebrospinal fluid (CSF) ctDNA. The results indicated that CSF ctDNA had a greater ability than plasma ctDNA to comprehensively represent the mutational landscape of BM, with CSF ctDNA detecting all BM mutations in 83.33% of patients, while plasma ctDNA was only 27.78%. Mutant allele frequency (MAF) in CSF ctDNA was highly correlated with the tumor size of BM (r = 0.95), and the mean MAF in CSF ctDNA was higher than that in plasma ctDNA (38.05% vs. 4.57%, respectively). MAF and tumor mutational burden in CSF ctDNA were strongly associated with those in BM (r = 0.96 and 0.97, respectively). Of note, CSF ctDNA had significantly higher concordance with BM than plasma ctDNA (99.33% vs. 67.44%), facilitating the identification of clinically relevant mutations. Moreover, we found that plasma ctDNA has stronger profiling performance, with a concordance of 93.01% in multiple brain metastases, equivalent to CSF ctDNA. Collectively, our study indicates that CSF ctDNA is superior to plasma ctDNA in accurately representing the profiling of single BM. Plasma ctDNA could be an alternative liquid biopsy material to be applied in multiple brain metastatic NSCLC.

Indexed as

Brain NeoplasmsCarcinoma, Non-Small-Cell LungCirculating Tumor DNALung NeoplasmsBiomarkers, TumorDNA, NeoplasmHumansMutationBiomarkers, TumorCirculating Tumor DNADNA, Neoplasmbrain metastasiscerebrospinal fluidcirculating tumor DNAliquid biopsynon-small-cell lung cancer

Identifiers

PMID36495130
PMCPMC10158766
OpenAlexW4311018514

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.